Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: Results from a global Candida antifungal surveillance program

Journal of Clinical Microbiology

Volumn 46, Issue 11, 2008, Pages 3585-3590

  Pfaller, M A ^a   Boyken, L B ^a   Hollis, R J ^a   Kroeger, J ^a   Messer, S A ^a   Tendolkar, S ^a   Diekema, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GUILLIERMONDII; CANDIDA KEFYR; CANDIDA KRUSEI; CANDIDA LUSITANIAE; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; HEALTH PROGRAM; HEALTH SURVEY; INCUBATION TIME; ISOLATION PROCEDURE; MEDICAL ERROR; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VALIDATION STUDY;

ANTIFUNGAL AGENTS; CANDIDA; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOLOGY;

CANDIDA; ISSATCHENKIA ORIENTALIS;

EID: 55849140118     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01391-08     Document Type: Article

References (41)

1. Arthington-Skaggs, B. A., W. Lee-Yang, M. A. Ciblak, J. P. Frade, M. E. Brandt, R. A. Hajjeh, L. H. Harrison, A. N. Sofair, and D. W. Warnock for the Candidemia Active Surveillance Group. 2002. Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates. Antimicrob. Agents Chemother. 46:2477-2481.
2. Baddley, J. W., M. Patel, M. Jones, G. Cloud, A. C. Smith, and S. A. Moser. 2004. Utility of real-time antifungal susceptibility testing for fluconazole in the treatment of candidemia. Diagn. Microbiol. Infect. Dis. 50:119-124.
3. Baddley, J. W., M. Patel, S. M. Bhavnani, S. A. Moser, and D. R. Andes. 2008. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob. Agents Chemother. 52:3022-3028.
4. Clinical and Laboratory Standards Institute. 2007. Zone diameter interpretive standards, corresponding minimal inhibitory concentration (MIC) interpretive breakpoints, and quality control limits for antifungal disk diffusion susceptibility testing of yeasts: informational supplement, M44-S2. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, 3rd ed., M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts: informational supplement, M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Collins, C. D., G. A. Eschenauer, S. L. Salo, and D. W. Newton. 2007. To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias. J. Clin. Microbiol. 45: 1884-1888.
8. Cuenca-Estrella, M., W. Lee-Yang, M. A. Ciblak, B. A. Arthington-Skaggs, E. Mellado, D. W. Warnock, and J. L. Rodriguez-Tudela. 2002. Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of Candida species. Antimicrob. Agents Chemother. 46:3644-3647.
9. Espinel-Ingroff, A., M. A. Pfaller, S. A. Messer, C. C. Knapp, S. Killian, H. A. Norris, and M. A. Ghannoum. 1999. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the National Committee for Clinical and Laboratory Standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeast-like organisms. J. Clin. Microbiol. 37:591-595.
10. Espinel-Ingroff, A., M. Pfaller, S. A. Messer, C. C Knapp, N. Holliday, and S. Killian. 2004. Multicenter comparison of Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J. Clin. Microbiol. 42:718-721.
11. Espinel-Ingroff, A., F. Barchiesi, M. Cuenca-Estrella, A. Fothergill, M. A. Pfaller, M. Rinaldi, J. L. Rodriguez-Tudela, and P. E. Verweij. 2005. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. J. Clin. Microbiol. 43:4535-4540.
12. Espinel-Ingroff, A., F. Barchiesi, M. Cuenca-Estrella, M. A. Pfaller, M. Rinaldi, J. L. Rodriguez-Tudela, and P. E. Verweij. 2005. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 43:3884-3889.
13. Forrest, G. 2006. Role of antifungal susceptibility testing in patient management. Curr. Opin. Infect. Dis. 19:538-543.
14. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
15. Hadley, S., J. A. Martinez, L. McDermott, B. Rapino, and D. R. Snydman. 2002. Real-time antifungal susceptibility screening aids management of invasive yeast infections in immunocompromised patients. J. Antimicrob. Chemother. 49:415-419.
16. Hazen, K. C., and S. A. Howell. 2007. Candida, Cryptococcus, and other yeasts of medical importance, p. 1762-1788. In P. R. Murray, E. J. Baron, J. H. Jorgensen, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
17. Hospenthal, D. R., C. K. Murray, and M. G. Rinaldi. 2004. The role of antifungal susceptibility in the therapy of candidiasis. Diagn. Microbiol. Infect. Dis. 48:153-160.
18. Magill, S. S., C. Shields, C. L. Sears, M. Choti, and W. G. Merz. 2006. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 44:529-535.
19. Masterton, R., G. Drusano, D. L. Paterson, and G. Park. 2003. Appropriate antimicrobial treatment in nosocomial infections - the clinical challenges. J. Hosp. Infect. 55(Suppl. 1):1-12.
20. Matar, M. J., L. Ostrosky-Zeichner, V. L. Paetznick, J. R. Rodriguez, E. Chan, and J. H. Rex. 2003. Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. Antimicrob. Agents Chemother. 47:1647-1651.
21. Metzler, C. M., and R. M. DeHaan. 1974. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J. Infect. Dis. 130:588-594.
22. Morrell, M., V. J. Fraser, and M. J. Kollef. 2005. Delaying empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob. Agents Chemother. 49:3640-3645.
23. NCCLS. 2004. Methods for antifungal disk diffusion susceptibility testing of yeasts: approved guideline, M44-A. NCCLS, Wayne, PA.
24. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Larsen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangino, and J. Lee. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
25. Ostrosky-Zeichner, L., J. H. Rex, M. A. Pfaller, D. J. Diekema, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob. Agents Chemother., in press.
26. Pappas, P. G., J. H. Rex, J. D. Sobel, et al. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
27. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and D. J. Diekema. 2002. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 46:1723-1727.
28. Pfaller, M. A., D. J. Diekema, S. A. Messer, L. Boyken, and R. J. Hollis. 2003. Activities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J. Clin. Microbiol. 41:1440-1446.
29. Pfaller, M. A., and D. J. Diekema. 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10(Suppl. 1):11-23.
30. Pfaller, M. A., K. C. Hazen, S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Comparison of results of fluconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS Global Antifungal Surveillance Program. J. Clin. Microbiol. 42:3607-3612.
31. Pfaller, M. A., A. Espinel-Ingroff, and R. N. Jones. 2004. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal plate for antifungal susceptibility testing of the new triazoles voriconazole, posaconazole, and ravuconazole. J. Clin. Microbiol. 42:4577-4580.
32. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
33. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
34. Pfaller, M. A., D. J. Diekema, D. L. Gibbs, et al. 2007. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45:1735-1745.
35. Pfaller, M. A., D. J. Diekema, G. W. Procop, and M. G. Rinaldi. 2007. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J. Clin. Microbiol. 45:796-802.
36. Pfaller, M. A., S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2008. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a Global Antifungal Surveillance Program. J. Clin. Microbiol. 46:551-559.
37. Revankar, S. G., W. R. Kirkpatrick, R. K. McAtee, A. W. Fothergill, S. W. Redding, M. G. Rinaldi, and T. F. Patterson. 1998. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method. J. Clin. Microbiol. 36:153-156.
38. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
39. Rex, J. H., P. W. Nelson, V. L. Paetznick, M. Lozano-Chiu, A. Espinel-Ingroff, and E. J. Anaissie. 1998. Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis. Antimicrob. Agents Chemother. 42:129-134.
40. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.
41. Rodriguez-Tudela, J. L., J. P. Donnelly, M. A. Pfaller, E. Chryssantou, P. Warn, D. W. Denning, A. Espinel-Ingroff, F. Barchiesi, and M. Cuenca-Estrella. 2007. Statistical analyses of correlation between fluconazole MICs for Candida spp. assessed by standard methods set forth by the European Committee on Antimicrobial Susceptibility Testing (E.Dis. 7.1) and CLSI (M27-A2). J. Clin. Microbiol. 45:109-111.